EUVIMEDEUVIMED entdecken
Open Access

Target Trial Emulation

Adriana Hung iD, Cole Beck iD, Robert A Greevy iD, Amber J Hackstadt iD, Tom A Elasy iD, Christianne L Roumie iD

Clinical Journal of the American Society of Nephrology · 2026-06 · 21 (6) · 997-1009

DOI: 10.2215/cjn.0000001033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 26.03.2026. Verfasst von Adriana Hung und 5 weiteren Autor:innen. Beteiligte Einrichtung: Veteran Administration Tennessee Valley VA Health Care System Geriatric Research Education Clinical Center (GRECC), Veterans' Wellbeing through Innov…. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Dipeptidyl-Peptidase IV Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Clinical Science Research and Development, Office of Research and Development, Division of Diabetes, Endocrinology, and Metabolic Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points Unknown if addition of newer diabetes medications is associated with kidney disease among older patients who were under recruited in clinical trials. In this target trial emulation, we report a protective association for kidney events and death for both glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter 2 inhibitor, compared with dipeptidyl peptidase-4 inhibitor. The association of glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter 2 inhibitor on kidney disease extended across multiple subgroups including short duration of use and in the older population.

Background

A trial emulation approach evaluated kidney outcomes for addition of three diabetes medications among Veterans, including older Veterans underrepresented in trials.

Methods

A retrospective cohort of Veterans with diabetes who were new users adding glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose cotransporter 2 inhibitors (SGLT2is), or dipeptidyl peptidase-4 inhibitors (DPP4is). Each group was followed until a composite of death or kidney event defined as a 50% decline in eGFR, kidney failure (transplant or dialysis) or censored for nonpersistence of drug class, loss of follow-up, and study end. The primary analysis used propensity score weights to compare the hazard of the composite outcome. The secondary analysis considered cause-specific hazard of kidney events with death as censoring. An Aalen–Johansen plot displayed individual outcomes of kidney event or death as a competing risk. Subgroup analyses evaluated Veterans by duration of use, age, eGFR, and urine protein.

Results

After propensity score weighting, the cohort included 42,684 GLP-1 RA, 44,198 SGLT2i, and 44,213 DPP4i episodes. The median age was 69 years, diabetes duration was 10.6 years (6.8–15.2), and eGFR was 75 ml/min per 1.73 m 2 (58–92). Event rates per 1000 person-years were 34.6 (33.3–36.0) versus 29.0 (27.8–30.3) versus 47.4 (46.0–48.9) for GLP-1 RA, SGLT2i, and DPP4i, respectively. There was a protective association for composite of kidney event and death for GLP-1 RA, hazard ratio (HR) 0.70 (0.67 to 0.74), and SGLT2i users (HR, 0.65 [0.61 to 0.68]) versus DPP4i. The results were similar for the cause-specific hazard of kidney event alone GLP-1 RA (HR, 0.72 [0.65 to 0.80]) and SGLT2i (HR, 0.48 [0.43 to 0.55]) and for subgroups.

Conclusions

GLP-1 RA and SGLT2i as add-on diabetes treatment were associated with lower composite and individual outcomes of kidney event and death. The association was similar across subgroups highlighting the value in primary prevention among older populations. Podcast This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2026_06_17_CJASNJune.21.6.6172.mp3

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsDiabetes Mellitus, Type 2Diabetic NephropathiesHypoglycemic AgentsHumansRetrospective StudiesFemaleMaleAgedMiddle AgedGlomerular Filtration Rate

Stichwörter der Autor:innen

clinical epidemiologydiabetes

Substanzen

Sodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • Veteran Administration Tennessee Valley VA Health Care System Geriatric Research Education Clinical Center (GRECC), Veterans' Wellbeing through Innovation, Systems Science and Experience in Learning Health Systems (VETW…
  • Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee.

ORCID-Profile: Adriana Hung, Cole Beck, Robert A Greevy, Amber J Hackstadt, Tom A Elasy, Christianne L Roumie

Förderung

  • Clinical Science Research and Development
  • Office of Research and Development
  • Division of Diabetes, Endocrinology, and Metabolic Diseases

Zitieren

APA

Hung, A., Beck, C., Greevy, R. A., Hackstadt, A. J., Elasy, T. A., & Roumie, C. L. (2026). Target Trial Emulation. Clinical Journal of the American Society of Nephrology, 21(6), 997-1009. https://doi.org/10.2215/cjn.0000001033

Vancouver

Hung A, Beck C, Greevy RA, Hackstadt AJ, Elasy TA, Roumie CL. Target Trial Emulation. Clinical Journal of the American Society of Nephrology. 2026;21(6):997-1009. doi:10.2215/cjn.0000001033

BibTeX
@article{Hung2026,
  author = {Hung, Adriana and Beck, Cole and Greevy, Robert A and Hackstadt, Amber J and Elasy, Tom A and Roumie, Christianne L},
  title = {Target Trial Emulation},
  journal = {Clinical Journal of the American Society of Nephrology},
  year = {2026},
  volume = {21},
  number = {6},
  pages = {997--1009},
  doi = {10.2215/cjn.0000001033}
}
Kostenlos starten →